Brief: Oryzon Gets US Patent Allowance For Vafidemstat
25/03/2026 06:29
March 25 (Reuters) - Oryzon Genomics SA ORY.MC: STRENGTHENS VAFIDEMSTAT PATENT PORTFOLIO WITH U.S. NOTICE OF ALLOWANCE U.S. PATENT EXPECTED TO REMAIN IN FORCE UNTIL AT LEAST 2040, EXCLUDING ANY POTENTIAL PATENT TERM ADJUSTMENTS OR EXTENSIONS PATENT PORTFOLIO COVERS THE USE OF VAFIDEMSTAT FOR TREATING NON-AGGRESSIVE SYMPTOMS OF BORDERLINE PERSONALITY DISORDER Source text Further company coverage: ORY.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28